Danish healthcare company Novo Nordisk and the William J. Clinton Foundation are looking at opportunities to collaborate on diabetes issues. Bill Clinton, the former US president, was one of the keynote speakers at the Global Changing Diabetes Leadership Forum, held in New York 13-14 March. The Forum, hosted by Novo Nordisk, gathered together policymakers, government officials, international organisations, patient organisations, healthcare professionals, people with diabetes and media from 20 countries.
At the Forum, Novo Nordisk president and CEO Lars Rebien Sørensen asked Mr. Clinton if he saw opportunities for a collaboration between the William J. Clinton Foundation and the World Diabetes Foundation, established by Novo Nordisk in 2001.
Clinton replied: "It would please me. Let my people meet your people and look at what countries we are working in, and where there are problems on which we can collaborate to solve."
Lars Rebien Sørensen was very satisfied with the response: "Now we can start looking at specific opportunities. We operate in the same countries, and there are great advantages in collaborating – we can gain a lot more penetration power instead of competing."
Bill Clinton pointed out that he had gained a much greater understanding in recent years of how chronic diseases such like diabetes create a giant problem, not just in the US, but in the entire world. 246 million people suffer from diabetes worldwide. Each year 7 million people are diagnosed with diabetes, and if the trend continues 380 million people will suffer from the disease by 2025.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company also has a leading position in haemostasis management, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. The news was reported by national daily newspaper Berlingske Tidende and on the Novo Nordisk website.